IP Library Granted Patent US 8,912,144
Granted Patent B2
US 8,912,144 · App. 12/790,515 · Granted Dec 16, 2014

Method for treating stroke via administration of NEP1-40 and inosine

Inventor: Larry I. Benowitz (Newton, MA)
Assignee: Children's Medical Center Corporation
A61K38/1709A61K48/00C12N2750/14145C12N2750/14143A61K31/7076A61K48/005C12N15/86
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,912,144
App. No.
12/790,515
Granted
Dec 16, 2014
Kind
B2
Abstract

Disclosed herein is a method for stimulating axonal outgrowth of central nervous system (CNS) neurons comprising contacting the CNS neurons with an effective amount of NEP1-40 and inosine, to thereby stimulate axonal outgrowth. The method may further comprise contacting the CNS neurons with a cAMP modulator that increases the concentration of intracellular cAMP. Also disclosed is a method for treating a neurological disorder selected from the group consisting of traumatic brain injury, stroke, spinal cord injury, optic neuropathy, retinal nerve damage and optic nerve damage, in a patient in need thereof comprising administering an effective amount of NEP1-40 and inosine to the patient.

Claims (6)

1. A method for stimulating axonal outgrowth of mammalian central nervous system (CNS) neurons damaged by stroke comprising contacting the CNS neurons with an effective amount of NEP1-40 and inosine, to thereby stimulate axonal outgrowth.

2. The method of claim 1 , further comprising contacting the CNS neurons with a cAMP modulator that increases the concentration of intracellular cAMP.

3. The method of claim 2 , wherein the cAMP modulator is selected from the group consisting of: cAMP analogues, activators of G protein coupled receptors that activate cAMP, adenylate cyclase activators, calcium ionophores, and phosphodiesterase inhibitors.

4. A method for treating stroke in a patient in need thereof comprising administering an effective amount of NEP1-40 and inosine to the patient, to thereby contact and stimulate axonal outgrowth of central nervous system (CNS) neurons damaged by stroke, to thereby treat the stroke.

5. The method of claim 4 , wherein the NEP1-40 and inosine are administered following an injury to the CNS, to thereby re-establish neural connectivity and/or function of the CNS neurons after the CNS injury.

6. The method of claim 4 , wherein the NEP1-40 and inosine are administered by a route selected from the group consisting of pulmonary, internal topical, interdermal, intravenous, subcutaneous, intranasal, epidermal, ophthalmic, oral, intraventricular, and intrathecal.

Assignments (3)
CONFIRMATORY LICENSE Recorded Feb 27, 2023
From: BOSTON CHILDREN'S HOSPITAL
To: NIH-DEITR
Reel/Frame 062882/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2010
From: BENOWITZ, LARRY I.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 025467/0673 →
CONFIRMATORY LICENSE Recorded Sep 17, 2010
From: CHILDREN'S HOSPITAL (BOSTON)
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025010/0427 →
Continuity (3)
Continuation In Part 10580364
Provisional Application 60529833 · Dec 16, 2003
Related Publication 20110071088A1 · Mar 24, 2011